ЕРЛОТИНІБ-МІЛІ-100

ਉਤਪਾਦ ਝਲਕ

About ЕРЛОТИНІБ-МІЛІ-100

ЕРЛОТИНІБ-МІЛІ-100 is a prescription medication containing the active ingredient Erlotinib, used in the treatment of non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. It belongs to the class of tyrosine kinase inhibitors.

Key Benefits & Uses

• Treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations
• Monotherapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
• Combination therapy with chemotherapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations

Active Ingredient & Action

Erlotinib, the active ingredient in ЕРЛОТИНІБ-МІЛІ-100, is a tyrosine kinase inhibitor that selectively targets the epidermal growth factor receptor (EGFR) tyrosine kinase. By inhibiting the EGFR tyrosine kinase, Erlotinib blocks the signal transduction pathway that promotes cell proliferation and survival, leading to the inhibition of tumor growth.

Important Notes

ЕРЛОТИНІБ-МІЛІ-100 is available only by prescription. It is essential to follow the recommended dosage and administration instructions provided by your healthcare provider. Patients with a history of interstitial lung disease or radiation pneumonitis should be closely monitored while taking Erlotinib. Common side effects may include rash, diarrhea, fatigue, and nausea. Consult your healthcare provider for more information on potential side effects and contraindications.